Photobiomodulation Therapy Delays Dry AMD Progression

Multiwavelength PBM approach shows visual acuity and disease morphology benefits.

By: Samuel Asanad, MD, David S. Boyer, MD

Retinal Physician March 1, 2025 Vol 22, Issue March 2025 Page(s): 8-11

Clinical Report: Photobiomodulation Therapy Delays Dry AMD Progression

Overview

{'FDA_approval_date': 'November 2022'}

Background

Age-related macular degeneration (AMD) is a leading cause of severe vision loss in older adults, particularly in its dry form, which progresses slowly and offers a critical window for intervention. Current treatment options for early to intermediate stages of dry AMD are limited, primarily relying on antioxidant supplementation with modest efficacy. Photobiomodulation represents an innovative, noninvasive approach that utilizes specific wavelengths of light to promote cellular health and potentially alter disease progression.

Data Highlights

Study	Outcome	Results
LIGHTSITE III	BCVA Improvement	+6.2 letters gain at Month 21 vs. sham (p=0.0036)
LIGHTSITE III	Geographic Atrophy Incidence	Lower incidence compared to sham

Key Findings

{'drusen_volume_reduction': 'Include specific metrics or percentages.'}

Clinical Implications

{'monitoring_parameters': 'Specify parameters for ongoing monitoring.'}

Conclusion

{'further_research': 'Emphasize the need for validation of long-term efficacy and safety.'}

PentaVision

Retinal Physician